BiomX (PHGE) Non-Current Assets (2018 - 2026)
BiomX (PHGE) posted Non-Current Assets of $208000.0 for Q1 2026, down 97.9% sequentially from $9.9 million in Q4 2025, and down 99.06% YoY from $22.1 million in Q1 2025.
BiomX (PHGE) Non-Current Assets (2018 - 2026) Analysis & Trends
BiomX has reported Non-Current Assets for 9 years, with the latest figure at $208000.0 in Q1 2026.
- Quarterly Non-Current Assets fell 99.06% year-over-year to $208000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $212.6 million (up 861.3% YoY) and the FY2025 annual result came in at $9.9 million, down 56.37% from the prior year.
- Non-Current Assets declined to $208000.0 in Q1 2026 per PHGE's latest filing, from $9.9 million in the prior quarter.
- Over five years, Non-Current Assets peaked at $33.5 million in Q2 2024 and troughed at $208000.0 in Q1 2026.
- A 5-year average of $14.3 million and a median of $10.0 million in 2022 frame the typical range for Non-Current Assets.
- The sharpest annual moves came in 2024 and 2026: Non-Current Assets soared 315.95% in 2024, then tumbled 99.06% in 2026.
- Over 5 years, Non-Current Assets stood at $8.6 million in 2022, then retreated by 14.49% to $7.4 million in 2023, then jumped by 207.06% to $22.7 million in 2024, then sank by 56.37% to $9.9 million in 2025, then slumped by 97.9% to $208000.0 in 2026.
- According to Business Quant data, Non-Current Assets over the past three periods registered $208000.0, $9.9 million, and $17.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 938.60 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 468.65 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 18.06 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 6.80 Bn |
| 10 | BiomX | 361,408.40 | -806,591.60 | - | 208,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 208,000.00 |
| Dec 31, 2025 | 9.91 Mn |
| Sep 30, 2025 | 17.31 Mn |
| Jun 30, 2025 | 21.42 Mn |
| Mar 31, 2025 | 22.12 Mn |
| Dec 31, 2024 | 22.71 Mn |
| Sep 30, 2024 | 31.66 Mn |
| Jun 30, 2024 | 33.54 Mn |
| Dec 31, 2023 | 7.40 Mn |
| Sep 30, 2023 | 7.76 Mn |
| Jun 30, 2023 | 8.06 Mn |
| Mar 31, 2023 | 8.47 Mn |
| Dec 31, 2022 | 8.65 Mn |
| Sep 30, 2022 | 9.37 Mn |
| Jun 30, 2022 | 10.07 Mn |
| Mar 31, 2022 | 10.64 Mn |
| Dec 31, 2021 | 11.35 Mn |
| Sep 30, 2021 | 12.00 Mn |
| Jun 30, 2021 | 11.81 Mn |
| Mar 31, 2021 | 10.53 Mn |